Aligos Therapeutics, Inc. Common Stock
ALGSAligos Therapeutics, Inc. is a biotechnology company focused on developing therapies for liver diseases, viral infections, and related conditions. The company leverages novel approaches in drug discovery and development to address unmet medical needs, particularly targeting hepatitis B virus (HBV) and other chronic liver diseases.
Company News
Aligos Therapeutics granted non-qualified stock options to purchase 14,100 shares for newly hired employees under their 2024 Inducement Plan, with shares vesting over a four-year period.
Aligos Therapeutics announced granting non-qualified stock options to newly hired employees, with 23,600 shares to be vested over a four-year period under their 2024 Inducement Plan.
Aligos Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted a non-qualified stock option to a newly hired employee as an inducement to join the company.
Aligos Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted a non-qualified stock option to a newly hired employee as an inducement to join the company.
Aligos Therapeutics, a clinical-stage biotechnology company, announced that it will report its fourth quarter 2024 financial results on March 10, 2025. The company is focused on developing therapies for liver and viral diseases.
